Alpha 2.0
Login Register
» Authors » Shinzoh Kudoh

Shinzoh Kudoh

Explore the profile of Shinzoh Kudoh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 71
Citations 3683
Followers 0
Related Specialties
Oncology
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Kazuto Hirata
Naruo Yoshimura
Tatsuo Kimura
Shigeki Mitsuoka
Kazuhiko Nakagawa
Masahiro Fukuoka
Koji Takeda
Minoru Takada
Shunichi Negoro
Tomohiro Suzumura
Published In
Osaka City Med J
J Clin Oncol
J Thorac Oncol
Lung Cancer
Anticancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Pulmonary Tuberculosis Incidence among Interferon-Gamma Release Assay-Positive Individuals with Latent Tuberculosis Infection and Fibrotic Lesions in a Vulnerable Urban Population in Osaka City, Japan, 2015-2021
Komukai J, Matsumoto K, Fukushima W, Kudoh S
Jpn J Infect Dis . 2023 Oct; 77(1):21-24. PMID: 37779028
Latent tuberculosis infection (LTBI) with fibrotic lesions (FL) can progress to active tuberculosis (TB). Most previous studies have used tuberculin skin tests, which have lower specificity than interferon-gamma release assays...
2.
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al.
J Clin Oncol . 2023 Feb; 41(6):1162-1171. PMID: 36791474
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated...
3.
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer
Takashima T, Nishimura S, Kawajiri H, Mizuyama Y, Nishimori T, Yamagata S, et al.
Anticancer Res . 2021 Oct; 41(10):5007-5014. PMID: 34593449
Background/aim: In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC)...
4.
[Treatment outcome of latent tuberculosis infection in persons with fibrotic pulmonary lesions]
Komukai J, Matsumoto K, Kudoh S, Okado A, Yoshiyama T, Yoshida H, et al.
Nihon Koshu Eisei Zasshi . 2021 Apr; 68(6):405-411. PMID: 33790095
Objective　This study aimed to evaluate the treatment outcome of latent tuberculosis infection (LTBI) in persons with fibrotic pulmonary lesions, treated with isoniazid (INH) or rifampicin (RFP) in Nishinari Ward,...
5.
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
Tokunaga S, Takashima T, Kashiwagi S, Noda S, Kawajiri H, Tokumoto M, et al.
Anticancer Res . 2019 Apr; 39(4):2053-2059. PMID: 30952749
Aim: This study was conducted in order to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus trastuzumab followed by 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) in a neoadjuvant chemotherapy (NAC)...
6.
Molecular Epidemiological Study on Passive Smoking and Estrogen Receptor Expression in Never-smokers with Non-small Cell Lung Cancer
Naoki Y, Kawaguchi T, Isa S, Shimizu S, Tamiya A, Asai K, et al.
Osaka City Med J . 2019 Feb; 62(2):77-84. PMID: 30721582
Background: Although sex hormones are thought to play an important role in the carcinogenesis of non-small cell lung cancer (NSCLC) in never-smokers, the causative mechanism remains unknown. Passive smoking (PS)...
7.
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer
Takashima T, Kawajiri H, Nishimori T, Tei S, Nishimura S, Yamagata S, et al.
Anticancer Res . 2017 Dec; 38(1):379-383. PMID: 29277798
Background/aim: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more...
8.
Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The...
Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, et al.
Am J Clin Oncol . 2017 Oct; 41(10):967-971. PMID: 29045265
Objectives: A phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small cell lung cancer was conducted. Materials And Methods: We used chemotherapy...
9.
Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer
Tezuka K, Takashima T, Kashiwagi S, Kawajiri H, Tokunaga S, Tei S, et al.
Mol Clin Oncol . 2017 Apr; 6(4):534-538. PMID: 28413662
Although the concurrent use of anthracycline-containing chemotherapy and taxane with trastuzumab are considered the treatment of choice for the primary systemic therapy of human epidermal growth factor receptor 2 (HER2)-overexpressing...
10.
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Takashima T, Tokunaga S, Tei S, Nishimura S, Kawajiri H, Kashiwagi S, et al.
Springerplus . 2016 Mar; 5:164. PMID: 27026861
The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also...